The company published a new study of average- and high-risk patients showing that the test better predicted metastasis in patients treated with radiation and hormonal therapy.
GenomeDx will use its Decipher Classifier and Genomics Resource Information Database to analyze samples, for tumor aggressiveness, and identify predictive signatures.
Results from a study using the database showed that patients with high expression of a certain gene signature had better outcomes with radiation therapy than without it.
Researchers are using GenomeDx's database to improve understanding of the genomic underpinnings of prostate cancer and advance personalized treatment strategies.
Launching the new biopsy-based version of Decipher, GenomeDx enters more direct competition with tests offered by Myriad Genetics and Genomic Health.
The firm will provide whole-genome profiling for Cedars-Sinai prostate cancer patients, who will also be tested with the Decipher Prostate Cancer Classifier.
The test is designed to predict prostate cancer aggressiveness and launched in the US in 2013.
The cloud-based Decipher GRID database will hold anonymized genomic data from the company's Decipher test and make it available to participating cancer centers.
The study shows that the genomic test may be able to differentiate between which patients would benefit from adjuvant radiation therapy or which do well with salvage treatment.
GenomeDx has implemented the software at its San Diego laboratory to track information related to the Decipher prostate test.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.